10-K · August 24, 2026
Bio-Techne delivered a sharp reported earnings recovery in fiscal 2026, but revenue was essentially flat at $1.215 billion and adjusted earnings declined 1% as product mix and pricing pressures offset growth. Protein…
Earnings analysis · 10-K
TECH earnings analysis
Filed October 28, 2026 · Our reading of the company's report
The latest report
This Form 10-K/A primarily adds Part III governance and compensation disclosures and explicitly does not change previously reported financial results; it contains no financial statements. Bio-Techne describes a broad,…
Read full summary
This Form 10-K/A primarily adds Part III governance and compensation disclosures and explicitly does not change previously reported financial results; it contains no financial statements. Bio-Techne describes a broad, internationally positioned life-science tools platform whose strategy relies on innovation, geographic expansion, and acquisitions, with fiscal 2026 revenue generally near incentive-plan targets but Diagnostics and Spatial Biology profitability below plan. The pending Merck KGaA merger is the dominant near-term issue, carrying substantial closing uncertainty and potentially significant retention, severance, and tax-related obligations.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Segment
- Protein Sciences segment incentive-plan revenue achievement: $875.4 million, or 97.7% of the $895.7 million target.
- Segment
- Diagnostics and Spatial Biology segment incentive-plan revenue achievement: $336.2 million, or 99.3% of the $338.6 million target.
What stood out
-
Broad life-science tools platform
The company’s stated strategy emphasizes core-product development, impactful innovation, geographic expansion, commercial execution, operational excellence, mergers and acquisitions, strategic collaborations, and talent retention. The filing says Bio-Techne sells “hundreds of thousands” of products and that almost half of its business comes from outside the United States.
-
M&A remains central to growth
Acquisitions are identified as a key growth strategy: the filing says Bio-Techne seeks to acquire companies that expand its product offerings and increase revenue. The Merck KGaA transaction would convert each outstanding share, other than specified excluded shares, into $73.00 in cash.
-
Revenue execution near plan
Fiscal 2026 incentive-plan results were close to company targets in revenue: company-wide revenue was $1,211.8 million, or 98.2% of the $1,234.3 million target, while Protein Sciences revenue was $875.4 million, or 97.7% of target.
-
Three-year growth roadmap
The company maintains a multi-year product and performance roadmap through fiscal 2028. Performance-based equity awards granted in fiscal 2026 use a three-year measurement period and weight consolidated organic revenue at 40%, adjusted EBITA at 35%, and relative total shareholder return at 25%.
-
Diagnostics revenue near target
Diagnostics and Spatial Biology revenue was $336.2 million, or 99.3% of its $338.6 million target, indicating comparatively strong revenue delivery even though profitability lagged plan.
-
Material international footprint
The company’s international positioning is meaningful: the filing states that almost half of Bio-Techne’s business comes from outside the United States, supporting continued geographic expansion but also broadening its addressable market.
What to watch
-
Merger closing and regulatory risk
The Merck KGaA merger had not closed as of June 30, 2026 or the filing date. Completion remains subject to remaining regulatory approvals and customary closing conditions, while the transaction would change control of the company and convert shares into $73.00 of cash.
-
Change-of-control cash obligations
The transaction creates significant retention, severance, and potential tax costs. Retention bonuses total $6.7 million across five continuing named executive officers, and preliminary estimated excise-tax reimbursement payments include $16.5 million for the CEO, $4.0 million for the Protein Sciences leader, $3.3 million for the general counsel, and $1.6 million for the Diagnostics and Spatial Biology leader.
-
Profitability and long-term target risk
Profitability execution was weaker than revenue execution, particularly in Diagnostics and Spatial Biology: segment EBITA was $37.8 million, or 86.6% of the $43.7 million target, versus company-wide EBITA of $387.5 million, or 96.4% of the $401.9 million target. In addition, the fiscal 2024–2026 performance awards achieved 0% payout for both revenue and EBITA because threshold performance was not reached.
Management's outlook
This Form 10-K/A contains no financial statements and does not provide numeric annual operating guidance. It states that the Merck KGaA merger remained unclosed at fiscal year-end; the previously disclosed expected closing timing was late 2026 or early 2027, subject to remaining approvals and closing conditions.
Earlier filings 4
10-Q · May 6, 2026
Bio-Techne Corporation (TECH) reported Q3 FY2026 results characterized by a revenue miss and modest EPS beat. Revenue was $311.4 million, reflecting a 2% decline year-over-year, while diluted EPS was $0.53, exceeding…
10-Q · February 4, 2026
Bio-Techne Corporation reported flat net sales of $295.9 million for Q2 2026, slightly beating revenue expectations by 1.6%. The company delivered adjusted EPS of $0.46, surpassing estimates by 15%. Notable segment…
10-Q · November 5, 2025
Bio-Techne's Q1 2026 report shows a 1% decline in revenue from the prior year, reflecting challenges in its Protein Sciences segment. However, gross margin improved to 65.6%, contributing to an adjusted EPS of $0.42,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.